topotecan has been researched along with Disease Models, Animal in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (8.11) | 18.2507 |
| 2000's | 13 (35.14) | 29.6817 |
| 2010's | 18 (48.65) | 24.3611 |
| 2020's | 3 (8.11) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Gilkeson, GS; Helke, KL; Oates, JC; Wang, X; Zhang, XK | 1 |
| Jiang, K; Lam, WC; Li, Y; Lo, ACY; Long, K; Lv, W; Wang, W; Yang, Y; Zhan, C | 1 |
| Boyan, BD; Cohen, DJ; Hyzy, SL; Kajan, I; Lawrence, KA; Mason, D; Olivares-Navarrete, R; Schwartz, Z; Williams, JK; Wilson, DS | 1 |
| Chen, Z; Fu, L; Guo, X; Luo, M; To, KKW; Wang, F; Wang, X; Yan, S; Zhang, J | 1 |
| Ackerman, JJH; Beeman, SC; Duan, C; Engelbach, JA; Garbow, JR; Ge, X; Perez-Torres, CJ; Rich, KM; Tsien, CI; Yang, R; Yuan, L | 1 |
| Chen, MZ; Hu, YB; Jin, JJ; Liu, HB; Lv, TF; Song, Y; Wan, B; Wang, XX; Xi, GM; Xu, WJ; Zhan, P; Zhang, XW; Zhu, SH | 1 |
| Liu, Z; Lowry, WE; Pohodich, AE; Raman, AT; Wan, YW; Yalamanchili, HK; Zoghbi, HY | 1 |
| Hoshino, Y; Jiang, X; Kurihara, T; Miwa, Y; Shoda, C; Tsubota, K | 1 |
| Billups, C; Davidoff, AM; Debelenko, LV; McGregor, L; Mercer, K; Morton, C; Pinto, EM; Ribeiro, RC; Rodriguez-Galindo, C; Zambetti, GP | 1 |
| Gallo, JM; Tiwari, AK; Zhang, R | 1 |
| Abramson, DH; Chantada, GL; Fabius, AW; Francis, JH; Schaiquevich, P | 1 |
| Larson, RS; Lovato, DM; Ricci, JW; Severns, V; Sklar, LA | 1 |
| Jamal, I; Jana, NR; Kumar, V; Sharma, A; Shekhar, S; Singh, BK; Vatsa, N | 1 |
| Chen, L; Chen, Z; Fu, L; Li, F; Wang, F; Wang, X; Zhang, W | 1 |
| Borgel, SD; Burkett, S; Butcher, DO; Hollingshead, M; Kenney, S; Raffeld, M; Schrump, DS; Shoemaker, RH; Stockwin, LH; Stone, G; Vistica, DT | 1 |
| Chandra, J; Coleman, RL; Danes, CG; Gershenson, DM; Han, LY; Jaffe, RB; Kamat, AA; Kim, HS; Lin, YG; Mangala, LS; Merritt, WM; Nick, AM; Shahzad, MM; Sood, AK; Spannuth, WA; Stone, RL | 1 |
| Carcaboso, AM; Dyer, MA; Egorin, M; Federico, S; Nemeth, KM; Schaiquevich, P; Shen, Y; Stewart, C; Zhang, J | 1 |
| Assanah, MC; Bruce, JN; Canoll, P; Gil, OD; Kangarlu, A; Linskey, K; Lopez, KA; Tannenbaum, AM; Yun, J | 1 |
| Cui, J; Li, C; Wang, C; Wei, N; Yang, H; Zhao, X | 1 |
| Nebbioso, M; Pascarella, A; Pescosolido, N; Scarsella, G; Stefanini, S; Tafani, M | 1 |
| Francia, G; Hackl, C; Kerbel, RS; Man, S; Milsom, C; Xu, P | 1 |
| Chen, Y; Cheng, C; Doughman, YQ; Dunwoodie, SL; Ebrahem, Q; Huang, TQ; Wang, Y; Watanabe, M; Yang, YC | 1 |
| Blazar, BR; Krieg, AM; Rodeberg, DA; Weigel, BJ | 1 |
| Beretta, GL; Brigliadori, G; Corna, E; De Cesare, M; Fabbri, F; Ricotti, L; Rosetti, M; Supino, R; Tesei, A; Ulivi, P; Zoli, W; Zunino, F | 1 |
| Dyer, MA; Egorin, M; Gray, JK; Laurie, NA; Leggas, M; Relling, M; Stewart, C; Zhang, J | 1 |
| Gupta, AA; Pappo, AS | 1 |
| Davidoff, AM; Dickson, PV; Fraga, CH; Hagedorn, NL; Hamner, JB; Ng, CY; Stewart, CF | 1 |
| Coleman, RL; Gaikwad, A; Saucier, JM; Smith, JA; Wolf, JK; Yu, J | 1 |
| Dalgard, C; Edelhauser, HF; Grossniklaus, HE; Lee, L; O'Brien, JM; Tsui, JY; Van Quill, KR | 1 |
| Danks, MK; Houghton, JA; Houghton, PJ; Luo, X; Stewart, CF; Thompson, J; Zamboni, WC | 1 |
| Inaba, M; Nomura, T; Ohnishi, Y; Sugiyama, Y; Tsuruo, T; Ueyama, Y | 1 |
| Chuang, N; Cohen, HW; O'Leary, JJ; Potmesil, M; Ren, CJ; Shapiro, RL | 1 |
| Cheshire, PJ; Danks, MK; Guichard, SM; Houghton, PJ; Lorsbach, R; Poquette, CA; Ragsdale, ST; Richmond, LB; Thompson, J; Webber, B | 1 |
| Huang, J; Kandel, JJ; Kim, E; Manley, C; Middlesworth, W; Moore, JT; O'Toole, K; Soffer, SZ; Stolar, C; Yamashiro, DJ; Yokoi, A | 1 |
| D'Argenio, DZ; Delauter, BJ; Egorin, MJ; Farese, AM; Kubat, NM; MacVittie, T; Potter, DM; Stewart, CF; Tubergen, D; Zamboni, WC | 1 |
| Huang, J; Kandel, JJ; Kim, ES; Manley, CA; McCrudden, KW; Middlesworth, W; Soffer, SZ; Yamashiro, DJ; Yokoi, A | 1 |
2 review(s) available for topotecan and Disease Models, Animal
| Article | Year |
|---|---|
OCULAR PHARMACOLOGY OF CHEMOTHERAPY FOR RETINOBLASTOMA.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Infusions, Intra-Arterial; Injections, Intraocular; Melphalan; Retinal Neoplasms; Retinoblastoma; Topotecan | 2017 |
New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.
Topics: Animals; Camptothecin; Child; Disease Models, Animal; Drug Design; Enzyme Inhibitors; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 2006 |
35 other study(ies) available for topotecan and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Camptothecin and Topotecan, Inhibitors of Transcription Factor Fli-1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB × NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal Cells.
Topics: Animals; Autoantibodies; Camptothecin; Cytokines; Disease Models, Animal; Female; Humans; Inflammation Mediators; Kidney; Lupus Nephritis; Proteinuria; Proto-Oncogene Protein c-fli-1; Topoisomerase Inhibitors; Topotecan | 2021 |
Green Light-Triggered Intraocular Drug Release for Intravenous Chemotherapy of Retinoblastoma.
Topics: Administration, Intravenous; Animals; Aqueous Humor; Blood-Retinal Barrier; Disease Models, Animal; Drug Carriers; Drug Liberation; Humans; Lenses, Intraocular; Light; Mice; Retina; Retinoblastoma; Topotecan; Vitreous Body | 2021 |
Inhibition of angiogenesis impairs bone healing in an in vivo murine rapid resynostosis model.
Topics: Angiogenesis Inhibitors; Animals; Bone Regeneration; Craniosynostoses; Delayed-Action Preparations; Disease Models, Animal; Drug Delivery Systems; Hydrogel, Polyethylene Glycol Dimethacrylate; Male; Mice, Inbred C57BL; Osteogenesis; Polyethylene Glycols; Polymethacrylic Acids; Topotecan; Vascular Endothelial Growth Factor A | 2017 |
Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Cell Membrane; Disease Models, Animal; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Humans; Inhibitory Concentration 50; Mice; Models, Biological; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolinones; Topotecan; Xenograft Model Antitumor Assays | 2018 |
Inhibitors of HIF-1α and CXCR4 Mitigate the Development of Radiation Necrosis in Mouse Brain.
Topics: Animals; Benzylamines; Brain; Cyclams; Disease Models, Animal; Disease Progression; Female; Heterocyclic Compounds; Hypoxia-Inducible Factor 1, alpha Subunit; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Necrosis; Radiation Injuries, Experimental; Receptors, CXCR4; Topotecan | 2018 |
Topotecan alleviates ventilator-induced lung injury via NF-κB pathway inhibition.
Topics: Acute Lung Injury; Animals; Apoptosis; Bronchoalveolar Lavage Fluid; Caspase 3; Cytokines; Disease Models, Animal; Epithelial Cells; Inflammation; Lung; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Peroxidase; Topotecan; Ventilator-Induced Lung Injury | 2018 |
Apparent bias toward long gene misregulation in MeCP2 syndromes disappears after controlling for baseline variations.
Topics: Animals; Base Pairing; Bias; Databases, Genetic; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulation; Humans; Methyl-CpG-Binding Protein 2; Mice; Principal Component Analysis; Rett Syndrome; RNA, Nuclear; Sequence Analysis, RNA; Syndrome; Topotecan | 2018 |
Pharmacological HIF inhibition prevents retinal neovascularization with improved visual function in a murine oxygen-induced retinopathy model.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Female; Hyperoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Mice, Inbred C57BL; Retinal Neovascularization; Topoisomerase I Inhibitors; Topotecan; Vascular Endothelial Growth Factor A; Visual Perception | 2019 |
Establishment and characterization of the first pediatric adrenocortical carcinoma xenograft model identifies topotecan as a potential chemotherapeutic agent.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Antineoplastic Agents; Child; Disease Models, Animal; Female; Gene Expression Profiling; Humans; Male; Mice; Recurrence; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models.
Topics: Animals; ATP-Binding Cassette Transporters; Disease Models, Animal; HEK293 Cells; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Topoisomerase I Inhibitors; Topotecan | 2013 |
Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Mice; Ovarian Neoplasms; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Disease Progression; DNA Topoisomerases, Type I; Gene Expression Regulation; Humans; Huntingtin Protein; Huntington Disease; Mice; Mice, Transgenic; Motor Activity; Neostriatum; Neurons; Topoisomerase I Inhibitors; Topotecan; Ubiquitin-Protein Ligases | 2017 |
ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Heterografts; Lapatinib; Mice, Nude; Mitoxantrone; Neoplasm Proteins; Neoplasm Transplantation; Quinazolines; Topotecan | 2017 |
Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD34; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bevacizumab; Chromosomes, Human, Pair 17; Chromosomes, Human, X; Disease Models, Animal; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Oncogene Proteins, Fusion; Sarcoma; Topotecan; Translocation, Genetic; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Topotecan; Vascular Endothelial Growth Factor A | 2009 |
Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Conjunctiva; Disease Models, Animal; Humans; Mice; Mice, Inbred C57BL; Rats; Retinal Neoplasms; Retinoblastoma; Topotecan; Visual Acuity; Xenograft Model Antitumor Assays | 2011 |
Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors.
Topics: Animals; Brain Neoplasms; Cell Survival; Disease Models, Animal; Glioblastoma; Immunohistochemistry; Neoplastic Stem Cells; Neuroglia; Platelet-Derived Growth Factor; Rats; Topotecan; Xenograft Model Antitumor Assays | 2011 |
Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Topics: Ammonium Sulfate; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Carcinoma, Lewis Lung; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Half-Life; Hand-Foot Syndrome; Humans; Injections, Intravenous; Leukemia L1210; Liposomes; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasms; Phosphatidylethanolamines; Polyethylene Glycols; Prostatic Neoplasms; Random Allocation; Rats; Rats, Wistar; Skin; Skin Diseases; Tissue Distribution; Topoisomerase I Inhibitors; Topotecan | 2012 |
Topotecan hydrochloride effects on retinal vessels in newborn rats.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Female; Fluorescein Angiography; Injections, Intravenous; Injections, Subcutaneous; Longevity; Male; Neovascularization, Physiologic; Rats; Rats, Wistar; Retina; Retinal Artery; Topoisomerase I Inhibitors; Topotecan | 2012 |
Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.
Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease Models, Animal; Female; Fluorouracil; HT29 Cells; Humans; Immunohistochemistry; Injections; Leucovorin; Liver Neoplasms; Mice; Mice, SCID; Organoplatinum Compounds; Survival Rate; Topotecan | 2013 |
Deletion of HIF-1α partially rescues the abnormal hyaloid vascular system in Cited2 conditional knockout mouse eyes.
Topics: Animals; Cell Differentiation; Disease Models, Animal; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lens, Crystalline; Mice; Mice, Knockout; Persistent Hyperplastic Primary Vitreous; Protein Binding; Repressor Proteins; Sequence Deletion; Topoisomerase I Inhibitors; Topotecan; Trans-Activators; Vascular Endothelial Growth Factor A | 2012 |
CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; CpG Islands; Cyclophosphamide; Disease Models, Animal; Drug Synergism; Female; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Oligonucleotides; Rhabdomyosarcoma, Embryonal; T-Lymphocytes; Time Factors; Topotecan | 2003 |
Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Camptothecin; Disease Models, Animal; DNA Topoisomerases, Type I; Down-Regulation; Female; Humans; Mice; Mice, Nude; Protease Inhibitors; Pyrazines; RNA, Messenger; S Phase; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2005 |
Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Etoposide; Eye; Humans; Mice; Mice, Knockout; Rats; Retinal Neoplasms; Retinoblastoma; Time Factors; Topotecan; Vincristine; Xenograft Model Antitumor Assays | 2005 |
Interferon beta-mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Blood Vessels; Disease Models, Animal; Genetic Vectors; Interferon-beta; Mice; Neoplasm Transplantation; Neuroblastoma; Topotecan | 2007 |
Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Mice; Mice, Nude; Ovarian Neoplasms; Platinum Compounds; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays | 2007 |
Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma.
Topics: Animals; Antigens, Polyomavirus Transforming; Antineoplastic Agents; Apoptosis; Cell Cycle; Conjunctiva; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Delivery Systems; Enzyme Inhibitors; Fibrin Tissue Adhesive; Injections; Luteinizing Hormone; Mice; Mice, Transgenic; Retinal Neoplasms; Retinoblastoma; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2008 |
Schedule-dependent efficacy of camptothecins in models of human cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neoplasms, Experimental; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |
Re: Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Humans; Mice; Neuroblastoma; Reproducibility of Results; Topotecan; Transplantation, Heterologous; Treatment Outcome | 1998 |
Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cornea; Disease Models, Animal; Fibroblast Growth Factor 2; Irinotecan; Mice; Mice, Inbred Strains; Neovascularization, Pathologic; Neovascularization, Physiologic; Topotecan; Vincristine | 1999 |
Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Mice; Mice, SCID; Neuroblastoma; Topotecan; Tumor Cells, Cultured; Vincristine | 2001 |
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Disease Models, Animal; Endothelial Growth Factors; In Situ Nick-End Labeling; Injections, Intraperitoneal; Kidney Neoplasms; Lymphokines; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Reference Values; Sensitivity and Specificity; Survival Rate; Topotecan; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Wilms Tumor | 2001 |
Pharmacodynamic model of topotecan-induced time course of neutropenia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Disease Models, Animal; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Metabolic Clearance Rate; Neoplasms; Neutropenia; Neutrophils; Recombinant Proteins; Time Factors; Topoisomerase I Inhibitors; Topotecan | 2001 |
Distinct response of experimental neuroblastoma to combination antiangiogenic strategies.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Endothelial Growth Factors; Enzyme Inhibitors; Female; Lymphokines; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neuroblastoma; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |